医学临床研究
醫學臨床研究
의학림상연구
JOURNAL OF CLINICAL RESEARCH
2014年
11期
2093-2094,2097
,共3页
高军%祝小英%石庆芳%王大庆%姜达
高軍%祝小英%石慶芳%王大慶%薑達
고군%축소영%석경방%왕대경%강체
沙立度胺/治疗应用%表柔比星/治疗应用%药物疗法,联合%肝肿瘤,实验性/药物疗法%肿瘤移植%小鼠,裸
沙立度胺/治療應用%錶柔比星/治療應用%藥物療法,聯閤%肝腫瘤,實驗性/藥物療法%腫瘤移植%小鼠,裸
사립도알/치료응용%표유비성/치료응용%약물요법,연합%간종류,실험성/약물요법%종류이식%소서,라
Thalidomide/TU%Epirubicin/TU%Drug Therapy,Combination%Liver Neoplasms,Experimental/DT%Neoplasm Transplantation%Mice,Nude
目的 探讨沙利度胺联合表阿霉素治疗小鼠 H22肝癌移植瘤的疗效。方法 培养 H22肿瘤细胞，制造皮下移植瘤小鼠模型60只。按照不同治疗方法将小鼠模型分成三组，每组20只，其中A组小鼠采用沙利度胺联合表阿霉素治疗；B组小鼠仅采用表阿霉素治疗；C组采用生理盐水对照，在治疗d7、d14、d21和d30测量各组小鼠肿瘤直径，统计治疗后12个月内三组小鼠死亡率。结果 A组小鼠d14肿瘤直径为（11．37 ± 1．03） mm ，显著短于同期B组（19．32 ± 1．12） mm和C组（28．39 ± 1．19） mm ；A组小鼠d30肿瘤直径为（9．23 ± 1．08）mm ，显著低于B组（12．23 ± 1．04 mm）和C组（29．29 ± 1．03 mm）。A组死亡率10％（2／20）显著低于B组45％（9／20）和C组80％（16／20）。结论 沙利度胺联合表阿霉素治疗小鼠 H22肝癌移植瘤疗效满意。
目的 探討沙利度胺聯閤錶阿黴素治療小鼠 H22肝癌移植瘤的療效。方法 培養 H22腫瘤細胞，製造皮下移植瘤小鼠模型60隻。按照不同治療方法將小鼠模型分成三組，每組20隻，其中A組小鼠採用沙利度胺聯閤錶阿黴素治療；B組小鼠僅採用錶阿黴素治療；C組採用生理鹽水對照，在治療d7、d14、d21和d30測量各組小鼠腫瘤直徑，統計治療後12箇月內三組小鼠死亡率。結果 A組小鼠d14腫瘤直徑為（11．37 ± 1．03） mm ，顯著短于同期B組（19．32 ± 1．12） mm和C組（28．39 ± 1．19） mm ；A組小鼠d30腫瘤直徑為（9．23 ± 1．08）mm ，顯著低于B組（12．23 ± 1．04 mm）和C組（29．29 ± 1．03 mm）。A組死亡率10％（2／20）顯著低于B組45％（9／20）和C組80％（16／20）。結論 沙利度胺聯閤錶阿黴素治療小鼠 H22肝癌移植瘤療效滿意。
목적 탐토사리도알연합표아매소치료소서 H22간암이식류적료효。방법 배양 H22종류세포，제조피하이식류소서모형60지。안조불동치료방법장소서모형분성삼조，매조20지，기중A조소서채용사리도알연합표아매소치료；B조소서부채용표아매소치료；C조채용생리염수대조，재치료d7、d14、d21화d30측량각조소서종류직경，통계치료후12개월내삼조소서사망솔。결과 A조소서d14종류직경위（11．37 ± 1．03） mm ，현저단우동기B조（19．32 ± 1．12） mm화C조（28．39 ± 1．19） mm ；A조소서d30종류직경위（9．23 ± 1．08）mm ，현저저우B조（12．23 ± 1．04 mm）화C조（29．29 ± 1．03 mm）。A조사망솔10％（2／20）현저저우B조45％（9／20）화C조80％（16／20）。결론 사리도알연합표아매소치료소서 H22간암이식류료효만의。
Objective]To explore the efficacy of thalidomide combined with epirubicin in the treatment of transplanted H22 hepatoma in mice .[Methods]H22 tumor cells were cultured ,and 60 mice with transplanted H22 hepatoma were established .According to the different treatment methods ,mouse models were divided in‐to group A( n=20) ,group B( n=20) and group C( n=20) .The mice of group A received thalidomide com‐bined with epirubicin therapy .The mice of group B only received epirubicin treatment .The mice of group C received normal saline .Tumor diameter at d7 ,d14 ,d21 and d30 was measured .Death rate of mice in 3 groups after 12 months was calculated .[Results] The tumor diameter of group A at d14 was (11 .37+ 1 .03)mm , which was significantly lower than that of B group[(19 .32 ± 1 .12)mm]( t = -28 .62 ,P =0 .000) and group C[(28 .39+1 .19)mm]( t = -59 .23 ,P =0 .000) .The tumor diameter of group A at d30 was (9 .23 ± 1 .08) mm ,which was significantly lower than that of group B[(12 .23 ± 1 .04)mm]( t = -3 .22 ,P =0 .002) and group C[(29 .29 ± 1 .03)mm]( t = -67 .38 ,P =0 .000) .The death rat of group A was 10% (2/20) ,which was significantly lower than that of group B(45% ,9/20) and group C(80% ,16/20) .[Conclusion] Thalido‐mide combined with epirubicin for the treatment of H22 transplanted hepatoma in mice has satisfactory effect .
